US › Healthcare

Immunic Inc (IMUX)

US · Healthcare · Biotechnology

$14.05-0.35%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-32.6M
Profit YoY
-27.9%
EPS
$-1.08
EPS estimate
$-0.96

EPS came in at -1.08 against a street estimate of -0.96 — a miss of 12.5%.

Key statistics

Market cap
$190.3M
Forward P/E
0.0
P/B
1.26
Book value
$11.10
EPS (TTM)
$-4.77
52-week high
$15.84
52-week low
$5.06
50-day MA
$14.19
200-day MA
$10.08
Beta
1.38

Analyst view

Analysts rate Immunic Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $41.90.

Shareholding

Insiders
0.97%
Institutions
46.82%

Largest institutional holders

FundStake
Bvf Inc5.62%
Vanguard Capital Management, LLC3.77%
Soleus Capital Management, L.P.3.30%
LAURION CAPITAL MANAGEMENT LP2.85%
Millennium Management LLC2.77%
Morgan Stanley - Brokerage Accounts2.41%
Nantahala Capital Management, LLC1.84%
683 Capital Management LLC1.80%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immunic Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.